It is not time to stop progesterone receptor testing in breast cancer

被引：40

作者：

Colomer, R ^{[1
]}

Beltran, M

Dorcas, J

Cortes-Funes, H

Hornedo, J

Valentin, V

Vargas, C

Mendiola, C

Ciruelos, E

机构：

[1] Inst Catala Oncol, Girona, Spain

[2] Hosp Univ 12 Octubre, Madrid, Spain

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期

关键词：

D O I：

10.1200/JCO.2005.05.203

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

引用

页码：3868 / 3869

页数：2

共 4 条

[1]

Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases [J].

Bardou, VJ ;

Arpino, G ;

Elledge, RM ;

Osborne, CK ;

Clark, GM .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (10) :1973-1979

[2]

Risk factors for breast cancer according to estrogen and progesterone receptor status [J].

Colditz, GA ;

Rosner, BA ;

Chen, WY ;

Holmes, MD ;

Hankinson, SE .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2004, 96 (03) :218-228

[3]

Time to stop progesterone receptor testing in breast cancer management [J].

Olivotto, IA ;

Truong, PT ;

Speers, CH ;

Bernstein, V ;

Allan, SJ ;

Kelly, SJ ;

Lesperance, ML .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (09) :1769-1770

[4]

Saccani Jotti G, 1994, J Clin Pathol, V47, P900, DOI 10.1136/jcp.47.10.900

← 1 →